Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel vs Interscalene Nerve Block for pain after RTSA
NCT03929146Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine in postoperative pain, sponsored by University of Cincinnati. Primary endpoints: Opioid Consumption at 72 hours, Visual Analog Scale Pain Scores at 72 hours and 1 more. Started Feb 2019; status: completed.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03929146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929146.